Latest news with #ApiamAnimalHealth
Yahoo
02-05-2025
- Business
- Yahoo
Shareholders in Apiam Animal Health (ASX:AHX) are in the red if they invested three years ago
Apiam Animal Health Limited (ASX:AHX) shareholders should be happy to see the share price up 16% in the last month. But that doesn't help the fact that the three year return is less impressive. In fact, the share price is down 47% in the last three years, falling well short of the market return. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). Apiam Animal Health saw its EPS decline at a compound rate of 72% per year, over the last three years. This was, in part, due to extraordinary items impacting earnings. In comparison the 19% compound annual share price decline isn't as bad as the EPS drop-off. So, despite the prior disappointment, shareholders must have some confidence the situation will improve, longer term. This positive sentiment is also reflected in the generous P/E ratio of 622.80. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. This free interactive report on Apiam Animal Health's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further. It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Apiam Animal Health's TSR for the last 3 years was -41%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return. It's nice to see that Apiam Animal Health shareholders have received a total shareholder return of 13% over the last year. That's including the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 0.5% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 5 warning signs we've spotted with Apiam Animal Health (including 1 which doesn't sit too well with us) . There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
ABC News
24-04-2025
- Health
- ABC News
Pork industry waits for JEV vaccine three years after viral outbreak
Australia's $6 billion pork industry has been waiting for a vaccine against the Japanese encephalitis virus (JEV) for three years since its outbreak. Nine people have died from the virus since 2021, including two in Queensland this year. A vaccine exists for humans, but two separate pig vaccines are yet to clear federal approval processes. It comes as primary producers do everything they can to combat the mosquito-borne virus that causes significant reproductive issues in sows and has cost the pork industry millions of dollars. Emergency permits The Australian Pesticides and Veterinary Medicines Authority (APVMA) said it was assessing two emergency use permit applications, which would allow scientists to trial their vaccines in piggeries. The competing vaccines have been developed primarily by the University of Queensland and veterinary company Apiam Animal Health. Chris Richards says he has 100,000 doses of a safe and effective vaccine. ( Supplied: Chris Richards ) Apiam Animal Health chief executive Chris Richards said he lodged his application on March 14, it passed the preliminary assessment two days later, and was told by the APVMA he would hear back within two weeks. He said he had been waiting for six weeks. He said the company had the capacity to vaccinate 50,000 sows within two weeks of emergency approval. "We haven't … really been notified that there are any deficiencies in the application," he said. "But also haven't been updated as to when that might be processed. "If we got an emergency use permit today, we'd be able to vaccinate most of those sows that are in the affected areas in the next two weeks." Feeling forgotten Farmers have been told their best defence is mosquito controls as The most recent detection was at the Betta Pork facility in Biloela. Director Laurie Brosnan said he was following industry best practice to keep his piggery safe, but it was not enough without an effective vaccine. He said Betta Pork had an independent contractor who sprayed open waterways, puddles, and other areas "at a considerable cost". "We also treat the animals to protect them against JEV," he said. "It's just unfortunate that there's only so much you can do." Laurie Brosnan says he is frustrated with the wait for a vaccine. ( Supplied: Laurie Brosnan ) He said he felt his industry had been forgotten. "I can't help but feel that the pig industry is not front of mind," he said. "I understand we're in election time, and politicians make promises as they do. "I still feel that the government isn't prioritising or even giving the pig industry a fair go." Top concern Australian Pork chief executive Margo Andrea said JEV was a top concern for the industry. "The previous outbreak in 2022 cost the industry millions of dollars and significantly impacted operations for piggeries across four states," she said. "Three years later, JEV continues to contribute to losses for producers and their communities. "We will continue pushing for a vaccine that will help keep our herds safe and healthy and help safeguard our producers' livelihoods." Growing need University of Queensland Associate Professor Jody Peters, who oversaw the development of one of the vaccines, said there was enough data to show that it was safe and effective. Jody Peters (right) looks at cells used for vaccines with Jessica Harrison. ( Supplied: University of Queensland ) Dr Peters said her team started working on it as soon as they were notified of the first JEV outbreak in Australia in early 2022. "The initial trials occurred at the end of 2022, and some additional trials occurred in 2023," she said. "I think we have got sufficient data to prove that it is effective, and it is safe. "But, ultimately, it is up to the regulatory bodies to determine whether we have produced enough data to date." Dr Peters said the need for a commercially available vaccine was growing. "With all of the flooding that's occurred recently, the mosquito that is likely the culprit for transmitting the virus would have bred up huge populations," she said. "I am incredibly frustrated, as are pig farmers, with how long it is taking to get these approvals across the line. "But I do believe that we will have a vaccine on the market in the future." ABC Southern Qld — local news in your inbox Get our local newsletter, delivered free each Wednesday Your information is being handled in accordance with the Email address Subscribe
Yahoo
03-03-2025
- Business
- Yahoo
Apiam Animal Health First Half 2025 Earnings: AU$0.008 loss per share (vs AU$0.018 profit in 1H 2024)
Revenue: AU$106.2m (up 1.7% from 1H 2024). Net loss: AU$1.52m (down by 146% from AU$3.28m profit in 1H 2024). AU$0.008 loss per share (down from AU$0.018 profit in 1H 2024). All figures shown in the chart above are for the trailing 12 month (TTM) period Apiam Animal Health shares are down 13% from a week ago. You should learn about the 6 warning signs we've spotted with Apiam Animal Health (including 2 which shouldn't be ignored). Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
28-02-2025
- Business
- Yahoo
Apiam Animal Health (ASX:AHX) Has Announced A Dividend Of A$0.01
Apiam Animal Health Limited (ASX:AHX) will pay a dividend of A$0.01 on the 28th of March. This makes the dividend yield 5.4%, which will augment investor returns quite nicely. View our latest analysis for Apiam Animal Health Impressive dividend yields are good, but this doesn't matter much if the payments can't be sustained. Prior to this announcement, the company was paying out 2,837% of what it was earning, however the dividend was quite comfortably covered by free cash flows at a cash payout ratio of only 28%. Generally, we think cash is more important than accounting measures of profit, so with the cash flows easily covering the dividend, we don't think there is much reason to worry. Looking forward, EPS could fall by 52.8% if the company can't turn things around from the last few years. Assuming the dividend continues along recent trends, we believe the payout ratio could reach 6,139%, which could put the dividend under pressure if earnings don't start to improve. Even in its relatively short history, the company has reduced the dividend at least once. This suggests that the dividend might not be the most reliable. The annual payment during the last 8 years was A$0.016 in 2017, and the most recent fiscal year payment was A$0.02. This means that it has been growing its distributions at 2.8% per annum over that time. The dividend has seen some fluctuations in the past, so even though the dividend was raised this year, we should remember that it has been cut in the past. With a relatively unstable dividend, it's even more important to see if earnings per share is growing. Apiam Animal Health's earnings per share has shrunk at 53% a year over the past five years. Dividend payments are likely to come under some pressure unless EPS can pull out of the nosedive it is in. Overall, it's nice to see a consistent dividend payment, but we think that longer term, the current level of payment might be unsustainable. The company is generating plenty of cash, which could maintain the dividend for a while, but the track record hasn't been great. Overall, we don't think this company has the makings of a good income stock. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. To that end, Apiam Animal Health has 6 warning signs (and 2 which shouldn't be ignored) we think you should know about. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
